Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

127.31 +2.95 (+2.37%)

Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

52 53 Next >

NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024 ↗

April 23, 2024

NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Novartis Ag (NVS) Q1 2024 Earnings Call Transcript ↗

April 23, 2024

NVS earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise ↗

April 23, 2024

Shares have risen markedly over the past two days and gained again Tuesday.

Via Investor's Business Daily

Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook ↗

April 23, 2024

Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.

Via Benzinga

Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback' ↗

April 23, 2024

The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fueled much of the market’s upside since 2023. Index futures rose...

Via Benzinga

Topics Bonds

Looking At Novartis's Recent Unusual Options Activity ↗

April 11, 2024

Via Benzinga

Top Analyst Reports For Novartis, American Express & ConocoPhillips ↗

April 22, 2024

Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).

Via Talk Markets

The Bad News Heading Into AbbVie's First-Quarter Earnings Report ↗

April 19, 2024

AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically."

Via Investor's Business Daily

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗

April 19, 2024

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel

Via Benzinga

Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years ↗

April 17, 2024

Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed.

Via Benzinga

2 High-Yield Dividend Stocks to Buy and Hold for 10 Years ↗

April 17, 2024

These income stocks look like good options at current levels.

Via The Motley Fool

Novartis AG (NYSE: NVS) Highlighted for Surprising Price Action

April 04, 2024

Via Investor Brand Network

1 Magnificent Dividend Stock to Buy and Hold ↗

March 24, 2024

The company's business went through some important changes last year.

Via The Motley Fool

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗

April 21, 2024

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

Via Benzinga

Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades ↗

April 16, 2024

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.

Via Benzinga

Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%. ↗

April 14, 2024

Think globally with this high-yielding ETF.

Via The Motley Fool

Topics ETFs

Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗

April 11, 2024

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth...

Via Benzinga

Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗

April 11, 2024

Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.

Via Investor's Business Daily

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

April 11, 2024

From Arvinas Inc.

Via GlobeNewswire

Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday? ↗

April 10, 2024

Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities.

Via Benzinga

SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today ↗

April 10, 2024

SoundHound AI stock is falling on Wednesday as investors in SOUN are worried about the company's plans for a secondary offering.

Via InvestorPlace

Topics Artificial Intelligence

Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost ↗

April 10, 2024

Alibaba stock is up on Wednesday as investors in BABA react to positive comments from cofounder Jack Ma concerning its leadership team.

Via InvestorPlace

Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts ↗

April 10, 2024

Novartis layoffs will see the healthcare company cut 680 jobs in the U.S. and Switzerland over the next two to three years.

Via InvestorPlace

Topics Workforce

Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says ↗

April 09, 2024

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho...

Via Benzinga

Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report ↗

April 09, 2024

Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools.

Via Benzinga

Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population ↗

April 08, 2024

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration...

Via Benzinga

Why Is Novartis Stock Trading Higher On Thursday? ↗

April 04, 2024

Novartis to file Pluvicto pre-taxane label expansion in 2H 2024 based on Phase 3 PSMAfore study data. Updated overall survival results show HR<1.0 in ITT population. rPFS consistent. Safety profile...

Via Benzinga

Harnessing AI for Drug Discovery: Top 3 Stocks to Watch ↗

March 26, 2024

As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly.

Via InvestorPlace

Topics Artificial Intelligence

Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund ↗

March 25, 2024

Norway's sovereign wealth fund has just five equity investments that represent nearly 13% of its total equity allocation.

Via Benzinga

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗

March 23, 2024

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

Via Talk Markets

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today